Kelly Emrick, MBA, Ph.D.

In a significant move aimed at reducing healthcare expenses for millions of Americans, the U.S. Department of Health and Human Services (HHS), through the Centers for Medicare & Medicaid Services (CMS), recently announced cost reductions for 54 prescription drugs covered under Medicare Part B. These reductions are directly linked to the Medicare Prescription Drug Inflation Rebate Program, established as part of the Biden-Harris Administration’s Inflation Reduction Act (IRA). This initiative aims to provide substantial financial relief to Medicare patients, particularly those managing chronic and life-threatening conditions such as cancer, osteoporosis, and pneumonia, by controlling the costs of medications that have risen faster than the inflation rate. This blog unpacks the significance of these measures, their broader implications for healthcare affordability, and how they fit into the ongoing healthcare reform efforts under the Biden-Harris Administration. The Inflation Reduction Act, signed into law in 2022, is a comprehensive policy to address the rising healthcare costs in the United States. A vital component of the IRA is the Medicare Prescription Drug Inflation Rebate Program, designed to discourage pharmaceutical companies from increasing drug prices without justification. Under this provision, drug manufacturers must provide rebates if their medication prices rise faster than inflation. The savings generated from these rebates are then passed on to Medicare beneficiaries in the form of lower out-of-pocket costs. Starting October 1, 2024, coinsurance rates for 54 drugs under Medicare Part B will be reduced, benefiting over 822,000 Americans who rely on these essential medications (HHS, 2024). The Inflation Reduction Act marks a significant shift from previous drug pricing policies, which had limited mechanisms for controlling pharmaceutical price inflation. Prior to the IRA, rising prescription drug costs were largely unchecked, resulting in a heavy financial burden for Medicare patients. The new measures represent a shift toward increased governmental intervention to protect consumers from exploitative pricing practices within the pharmaceutical industry.

The Inflation Reduction Act’s prescription drug provisions are not simply about providing temporary cost relief; they are part of a broader structural reform intended to reshape how healthcare costs are managed across the United States. By incentivizing manufacturers to keep price increases below inflation, the IRA addresses the root causes of drug price surges that have historically driven up healthcare expenses for vulnerable populations. Many older adults on Medicare, especially those with fixed incomes, have often faced difficult choices, such as rationing their medications due to high out-of-pocket costs. According to a 2023 survey by the Kaiser Family Foundation, nearly one in four Medicare beneficiaries reported skipping doses or not filling prescriptions due to cost concerns (KFF, 2023). The IRA’s provisions are designed to alleviate these pressures, ensuring that essential medications remain accessible. In addition to lowering coinsurance rates for selected Part B drugs, the Inflation Reduction Act also lays the foundation for future cost reductions through Medicare Part D. In August 2024, the Biden-Harris Administration announced new agreements to negotiate lower prices for ten high-cost medications covered under Part D, with expected savings projected to be $6 billion annually once these price changes are fully implemented in 2026 (HHS, 2024). This dual approach of tackling Part B and Part D costs represents a comprehensive strategy to alleviate millions of Medicare beneficiaries’ financial burdens. Another significant provision is the upcoming $2,000 annual cap on out-of-pocket prescription drug costs for all Medicare Part D beneficiaries, which is set to take effect in 2025. This cap represents a historic change in Medicare, ensuring no beneficiary will pay more than $2,000 annually for prescription drugs, significantly improving affordability for those with high medication needs. By capping out-of-pocket costs and negotiating drug prices directly, the Inflation Reduction Act aims to foster a more equitable healthcare system in which seniors and individuals with disabilities can access life-saving treatments without financial hardship.

The impact of these measures on Medicare beneficiaries cannot be overstated. For many individuals, even a modest reduction in medication costs can mean the difference between adhering to treatment protocols and experiencing health deterioration. For instance, Kymriah, a cancer treatment drug that previously posed an enormous cost burden, will see a significant reduction, potentially saving patients up to $3,000 in out-of-pocket expenses during the final quarter of 2024 (HHS, 2024). Such savings are transformative for individuals managing chronic conditions who might otherwise struggle to afford their medications. Furthermore, the Inflation Reduction Act aims to address health inequities by ensuring that people from marginalized communities who have historically faced barriers to affordable healthcare receive the financial support they need. Studies have shown that economic hardship is a critical factor influencing medication adherence, and by lowering costs, the IRA contributes to improved health outcomes for underrepresented groups (Berkowitz et al., 2023). These measures ultimately translate to fewer emergency room visits, fewer hospital admissions, and a higher quality of life for Medicare beneficiaries.

While the Inflation Reduction Act marks significant progress in drug pricing reform, it also faces challenges. Pharmaceutical companies are already pushing back, arguing that such regulations may stifle innovation and reduce the incentive to invest in new drug development. However, proponents say that the Act does not discourage innovation but instead seeks to hold pharmaceutical companies accountable for unjustified price increases, ensuring that profits are not prioritized over patient access to essential medications (Gaffney & Himmelstein, 2024). The negotiation provisions within the IRA are designed to balance reasonable profit margins for drug manufacturers and the need to maintain affordable access to healthcare. Implementing and enforcing these provisions will require robust oversight moving forward. The Centers for Medicare & Medicaid Services will monitor drug prices and ensure pharmaceutical companies comply with the new rules. Continued advocacy is also needed to expand these reforms beyond Medicare, potentially extending similar cost-saving measures to those with private insurance or uninsured.

Berkowitz, S. A., Seligman, H. K., & Choudhry, N. K. (2023). Economic hardship and medication adherence: Implications for Medicare reforms. Journal of Health Economics.

Gaffney, A., & Himmelstein, D. U. (2024). The impact of drug pricing reforms on pharmaceutical innovation. Health Affairs, 43(1), 45-56. https://www.healthaffairs.org/content/forefront/balancing-lower-u-s-prescription-drug-prices-and-innovation-part-1

Kaiser Family Foundation. (2023). Survey of Medicare beneficiaries on prescription drug affordability. https://www.kff.org

U.S. Department of Health and Human Services. (2024). HHS announces cost savings for 54 prescription drugs thanks to the Medicare inflation rebate program established by the Biden-Harris administration’s lower-cost prescription drug law. https://www.hhs.gov